Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31731259 | 0.87 | DDB1 (0.36) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL31160705 | 0.87 | DDB1 (0.36) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL31731245 | 0.87 | DDB1 (0.36) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL31731564 | 0.84 | DDB1 (0.34) | DDB1CRBNALDH1A1CYP1A2 | |
| SCHEMBL30990746 | 0.84 | DDB1 (0.32) | DDB1CRBN | |
| SCHEMBL31160670 | 0.83 | DDB1 (0.34) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL30990711 | 0.82 | DDB1 (0.35) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL30990692 | 0.82 | DDB1 (0.35) | DDB1CRBN | |
| SCHEMBL31160701 | 0.82 | DDB1 (0.35) | DDB1CRBN | |
| SCHEMBL31731318 | 0.81 | DGAT1 (0.32) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | SF1, SF3A1, SFXN1 | DDB1 1201/4885CRBN 2290/4885KDM4E 837/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | DDB1 363/4885CRBN 2904/4885KDM4E 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.